Adaptive Biotechnologies to Report Q1 2026 Earnings on May 5

Got story updates? Submit your updates here. ›

Adaptive Biotechnologies Corporation, a commercial-stage biotechnology company focused on harnessing the adaptive immune system to diagnose and treat disease, announced it will report its financial results for the first quarter of 2026 after the market close on Tuesday, May 5, 2026. The company will host a corresponding conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Why it matters

As a publicly traded biotech company, Adaptive Biotechnologies' quarterly earnings reports provide key insights into the performance and progress of its immune medicine platform and clinical pipeline. The company's ability to translate the genetics of the adaptive immune system into diagnostic and therapeutic products is closely watched by investors and the broader healthcare industry.

The details

Adaptive Biotechnologies is a commercial-stage biotechnology company that aims to transform the diagnosis and treatment of disease by harnessing the inherent biology of the adaptive immune system. The company's proprietary immune medicine platform allows it to reveal and translate the massive genetics of the adaptive immune system with scale, precision and speed. Adaptive Biotechnologies applies this platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine.

• Adaptive Biotechnologies will report its Q1 2026 financial results after market close on Tuesday, May 5, 2026.
• The company will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on May 5, 2026.

What’s next

Investors and analysts will be closely watching Adaptive Biotechnologies' Q1 2026 earnings report and conference call for updates on the company's financial performance, progress in its clinical pipeline, and strategic partnerships.